Paclitaxel

紫杉醇

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NamePaclitaxel
Drug Alias Name浆果赤霉素IIIpaclitaxelum太平洋紫杉醇IntaxelPaclitaxel liposomal +[50] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation promotersTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsUveal melanomaPlaque psoriasisVascular restenosis +[85] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[8] 
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[7] 
Original Approved Country/TerritoryUnited States
Original Approved Date1992/12/29
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesNovocure LtdZhejiang Zhida Pharmaceutical Co LtdGie Medical +[31] 
Inactive CompaniesBeijing Gorjest Technology Co LtdHanmi Pharmaceutical Co LtdDuke-Nus Academic Medicine Research Institute +[63] 
Active IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Diseases +[38] 
Inactive IndicationsUveal melanomaPlaque psoriasisVascular restenosis +[47] 

Other Information

ATC CodeL01CD01
Related LinksWikipediaDrugBankKEGG